Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling

Cancer Cell International

Volumn 9, Issue , 2009, Pages 25-

  Chesnokov, Viktor ^a   Sun, Chao ^a   Itakura, Keiichi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; GLUCOSAMINE; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 70350090622     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-9-25     Document Type: Article

References (34)

1. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food and Chemical Toxicology 2005, 43:187-201. 10.1016/j.fct.2004.11.006, 15621331.
2. Uldry M, Ibberson M, Hosokawa M, Thorens B. GLUT2 is a high affinity glucosamine transporter. FEBS letters 2002, 524:199-203. 10.1016/S0014-5793(02)03058-2, 12135767.
3. Wolosker H, Kline D, Bian Y, Blackshaw S, Cameron AM, Fralich TJ, Schnaar RL, Snyder SH. Molecularly cloned mammalian glucosamine-6-phosphate deaminase localized to transporting epithelium and lacks oscillin activity. FASEB J 1998, 12:91-99.
4. Wells L, Hart GW. O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. FEBS letters 2003, 546:154-158. 10.1016/S0014-5793(03)00641-0, 12829252.
5. Dahmer S, Schiller RM. Glucosamine. Am Fam Physician 2008, 78:471-476.
6. Quastel JH, Cantero A. Inhibition of tumor growth by D-glucosamine. Nature 1953, 171:252-254. 10.1038/171252a0, 13036842.
7. Molnar Z, Bekesi JG. Cytotoxic effects of D-Glucosamine on the ultrastructures of normal and neoplastic tissues in vivo. Cancer Res 1972, 32:756-765.
8. Friedman SJ, Skehan P. Membrane-active drugs potentiate the killing of tumor cells by D-glucosamine. Proc Natl Acad Sci USA 1980, 77:1172-1176. 10.1073/pnas.77.2.1172, 348447, 6928667.
9. Zhang L, Liu W-S, Han B-Q, Peng Y-F, Wang D-F. Antitumor activities of D-glucosamine and its derivatives. Journal of Zhejiang University SCIENCE B 2006, 7:608-614. 10.1631/jzus.2006.B0608, 1533750, 16845712.
10. Wang Z, Liang R, Huang G-S, Piao Y, Zhang Y-Q, Wang A-Q, Dong B-X, Feng J-L, Yang G-R, Guo Y. Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL. Apoptosis 2006, 11:1851-1860. 10.1007/s10495-006-9529-6, 16850161.
11. Levy DE, Darnell JE. STATs: Transcriptional control and biological impact. Nature Rev Mol Cell Biol 2002, 3:651-662.
12. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nature Rev Cancer 2004, 4:97-105.
13. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. Prostate 2002, 51:241-246. 10.1002/pros.10079, 11987152.
14. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002, 62:6659-6666.
15. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STA3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 2005, 93:70-80. 10.1038/sj.bjc.6602637, 2361492, 15970928.
16. Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, Carter B, Turkson J, Jove R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 2006, 5:621-629. 10.1158/1535-7163.MCT-05-0268, 16546976.
17. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Current Cancer Drug Targets 2006, 6:107-121. 10.2174/156800906776056491, 16529541.
18. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30. 10.3322/canjclin.55.1.10, 15661684.
19. Denmeade SR, Isaacs JT. Development of prostate cancer treatment: The good news. Prostate 2004, 58:211-224. 10.1002/pros.10360, 14743459.
20. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev Cancer 2001, 1:34-45.
21. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & Dev 1999, 13:1501-1512.
22. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997, 57:141-146.
23. Altieri DC. Validating survivin as a cancer therapeutic target. Nature Rev Cancer 2003, 3:46-54.
24. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF-S. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004, 3:11-20.
25. Oh HJ, Lee JS, Song DK, Shin DH, Jang BC, Suh SI, Park JW, Suh MH, Baek WK. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. Biochem Biophys Res Commun 2007, 360:840-845.
26. Sugibayashi R, Kiguchi Y, Shimizu T, Suzuki T, Hamada H, Takeda K. Up-regulation of p21WAF1/CIP1 levels leads to growth suppression of prostate cancer cell lines. Anticancer Res 2002, 22:713-720.
27. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR, Amin HM. Constitutive activation of JAK/STAT3 in colon carcinoma tumors and cell lines. Am J Pathol 2005, 167:969-980. 1603671, 16192633.
28. Masson E, Wiernsperger N, Lagarde M, El Bawab S. Glucosamine induces cell-cycle arrest and hypertrophy of mesangial cells: implication of gangliosides. Biochem J 2005, 388:537-544. 1138961, 15654767.
29. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005, 202:654-662.
30. Kim D-S, Park K-S, Jeong K-C, Lee BI, Lee C-H, Kim S-Y. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009, 273:243-249.
31. Kudlow JE. Post-translational modification by O-GlcNAc: Another way to change protein function. J Cell Biochem 2006, 98:1062-1075.
32. Gewinner C, Hart G, Zachara N, Cole R, Beisenherz-Huss C, Groner B. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 2004, 279:3563-3572.
33. Schwarz RT, Klenk HD. Inhibition of glycosylation of the influenza virus hemagglutinin. J Virol 1974, 14:1023-1034. 355615, 4473565.
34. Jang B-C, Sung S-H, Park J-G, Park J-W, Bae JH, Shin DH, Park G-Y, Han S-B, Suh S-I. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem 2007, 282:27622-27632.